Mizuho Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $23
Benzinga Newsdesk 21 hours ago
Analyst RatingsNewsPrice Target
Mizuho analyst Graig Suvannavejh maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $24 to $23.
Mizuho analyst Graig Suvannavejh maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $24 to $23.